XML 108 R95.htm IDEA: XBRL DOCUMENT
v3.21.2

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 2,111 | $ 2,138 | $ 6,238 | $ 5,814
Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 941 | 976 | 2,775 | 2,700
Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 469 | 432 | 1,393 | 1,086
OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 409 | 374 | 1,115 | 1,040
Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 269 | 329 | 884 | 908
Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 23 | 27 | 71 | 80
Bausch + Lomb |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 949 | 916 | 2,764 | 2,468
Bausch + Lomb | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 120 | 137 | 379 | 371
Bausch + Lomb | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 396 | 360 | 1,175 | 921
Bausch + Lomb | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 365 | 341 | 1,010 | 957
Bausch + Lomb | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 61 | 71 | 180 | 196
Bausch + Lomb | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 7 | 7 | 20 | 23
Salix |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 527 | 496 | 1,515 | 1,377
Salix | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 525 | 494 | 1,509 | 1,374
Salix | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 2 | 6 | 3
International Rx |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 271 | 308 | 890 | 848
International Rx | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 61 | 64 | 187 | 185
International Rx | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
International Rx | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 41 | 31 | 98 | 77
International Rx | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 161 | 204 | 579 | 553
International Rx | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 8 | 9 | 26 | 33
Ortho Dermatologics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 140 | 143 | 418 | 391
Ortho Dermatologics | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 62 | 65 | 186 | 211
Ortho Dermatologics | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 73 | 72 | 218 | 165
Ortho Dermatologics | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ortho Dermatologics | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ortho Dermatologics | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 5 | 6 | 14 | 15
Diversified Products |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 224 | 275 | 651 | 730
Diversified Products | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 173 | 216 | 514 | 559
Diversified Products | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Diversified Products | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 3 | 2 | 7 | 6
Diversified Products | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 47 | 54 | 125 | 159
Diversified Products | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 1 | $ 3 | $ 5 | $ 6

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |